ASEPA NEWS
ASEPA NEWSLETTERS
January 2020 Newsletter »
July 2019 Newsletter »
RECENT NEWS
March 9, 2020:
FDA draft guidance eliminates CV outcomes trial recommendation for diabetes drug approvals
February 15, 2020:
FDA recall on Medtronic pumps - 600 series
February 13, 2020:
FDA voluntary recall of anti-obesity drug Belviq
January 28, 2020:
FDA okays triple-combo pill for type 2 diabetes
January 16, 2020:
FDA Approves Semaglutide Injection for Cardiovascular Risk Reduction
https://www.mdmag.com/medical-news/fda-semaglutide-injection-ozempic-cardiovascular-reduction
January 6, 2020:
Fiasp is now approved for children with diabetes
December 13, 2019:
FDA approves Tandem Diabetes Care Control IQ Technology, a integrated insulin pump + continuous glucose sensor
October 22, 2019:
FDA OKs Faster-Acting Insulin Aspart for Pump Use (Fiasp)
medscape.com/viewarticle/920162
October 21, 2019:
FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes (Farxiga)
medscape.com/viewarticle/920093
September 30, 2019:
FDA OKs Canagliflozin to Curtail Diabetic Kidney Disease (Invokana)
medscape.com/viewarticle/919184
September 20, 2019:
FDA OKs 'Game-Changer' Oral GLP-1 Agonist for Type 2 Diabetes (Rybelsus)
medscape.com/viewarticle/918772
September 12, 2019:
FDA Approves New Glucagon Pen to Treat Hypoglycemia
diatribe.org/fda-approves-potentially-life-saving-gvoke-xeris-ready-use-glucagon
Bulletin from The Endocrine Society: NATPARA Recall
https://www.magnetmail.net/actions/email_web_version.cfm
CMHC’s Monthly Newsletter:
cardiometabolichealth.org/newsletter.html
MEETINGS
ASEPA members meet twice a year at the following conferences: AAPA and AACE. We also meet informally at the MEDS East and MEDS West conferences.
Throughout the year, board members communicate frequently via email and conference calls.